Haematologic malignancies
Research activity in indolent B-cell non-Hodgkin lymphoma includes relapsed and refractory disease settings, with attention to follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma.
- Rituximab-based combinations
- Acalabrutinib
- CD32b targeting
The sponsor’s work in this area centres on antibody-based approaches for lymphoma subtypes with limited treatment options.
Advanced solid tumours
Clinical research spans a broad range of advanced solid tumors, including disease that has progressed after prior PD-1 or PD-L1 therapy.
- Pembrolizumab combinations
- Immune checkpoint targeting
- Monoclonal antibody therapies
Interest extends to tumour types such as non-small cell lung cancer and uveal melanoma.
Melanoma
Studies in unresectable or metastatic melanoma focus on immunotherapy combinations designed to address advanced disease.
- Ipilimumab
- Pembrolizumab
- FcγRIIB modulation
This area reflects ongoing interest in combination regimens for difficult-to-treat melanoma populations.
Immune-oncology targets
The sponsor investigates TNFR2 and FcγRIIB (CD32b) as therapeutic targets across advanced malignancies and advanced solid tumors.
- BI-1808
- BI-1910
- BI-1607
These programs are positioned within antibody-based immuno-oncology research.
